IMM.L • LSE
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold IMM.L in your mock portfolio yet.
ImmuPharma is currently loss-making, as indicated by its negative EPS and negative PE ratio. The very small absolute loss per share (-0.01) suggests limited current earnings power rather than deep profitability problems being resolved. Overall, the data points to an early-stage or pre-commercial profile where valuation depends more on future prospects than current financial strength.
The stock has risen 12.9% over the last month and is trading above its 200-day moving average, signaling a constructive intermediate trend. However, the RSI around 57 is in neutral territory, suggesting neither overbought nor oversold conditions. Overall, the technical setup leans mildly positive but does not yet indicate a strong momentum-driven breakout.
Alternative data suggests limited current commercial traction and modest investor or customer engagement. Website traffic is very low, job postings are at zero, and social media followings are small with only marginal growth. These indicators are consistent with a small, early-stage biotech with constrained growth visibility in the near term.
ImmuPharma’s stock shows some technical improvement, trading above its 200-day moving average with a solid one-month gain, but this is not yet supported by strong fundamentals or robust alternative data signals. The company remains loss-making with limited evidence of commercial scale or growing operational footprint. Overall, the setup appears speculative and event-driven, with a balanced risk-reward profile that is neither clearly bullish nor decisively bearish based on the provided data.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
IMM.L (ImmuPharma) has experienced significant price changes, with a 33.0% increase over one day and a 44.4% increase over the past week. The stock's volume is 5.1 times the average, and it is currently flagged for high volatility, which is consistent with the heightened activity around this stock.
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: